Development of novel linkers to conjugate pharmacophores to a carrier antibody.
We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-defined therapeutic benefits and improved pharmacokinetic properties. These linkers expand the array of tools available for bioconjugation of pharmacophores to antibodies.
CovX Research, Pfizer Worldwide Research and Development, 9381 Judicial Drive, Suite 200, San Diego, CA 92121, USA. moorthy.palanki@pfizer.com
Moorthy S S
MS
Palanki
Abhijit
A
Bhat
Rodney W
RW
Lappe
Bin
B
Liu
Bryan
B
Oates
John
J
Rizzo
Nebojsa
N
Stankovic
Curt
C
Bradshaw
D000906:Antibodies / Q000276:immunology*; D004337:Drug Carriers / Q000737:chemistry; D004355:Drug Stability; D005978:Glutathione / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D008301:Maleimides / Q000737:chemistry*; D009841:Oligonucleotides / Q000737:chemistry / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D011506:Proteins / Q000235:genetics / Q000378:metabolism; D013696:Temperature
D000906:Antibodies; D004337:Drug Carriers; D008301:Maleimides; D009841:Oligonucleotides; D010455:Peptides; D011506:Proteins; C043592:maleimide; D005978:Glutathione